[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-353474-105":59,"doc-detail-353474-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","targeted-radionuclide-therapy-current-landscape-and-combination-approaches-to-improve-oncology-outcomes","Targeted Radionuclide Therapy - Current Landscape and Combination Approaches to Improve Oncology Outcomes","","Targeted radionuclide therapy (TRT) is presented as an emerging oncology modality that delivers internal, DNA-damaging radiation selectively to tumor sites. TRT uses a radionuclide, a chelator-based linking complex, and a tumor-targeting binding moiety, with theranostic pairs enabling imaging and treatment. Although approved TRT agents show early promise, relapse after monotherapy limits outcomes. The review outlines key physical and chemical properties of common alpha- and beta-emitters and evaluates combination rationales with modalities such as hormone therapy, DNA damage repair inhibitors, immunotherapy, chemotherapy, and external beam radiotherapy, supported by preclinical evidence and ongoing trials, plus future biomarkers and radionuclide advances.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/targeted-radionuclide-therapy-current-landscape-and-combination-approaches-to-improve-oncology-outcomes/353474/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/targeted-radionuclide-therapy-current-landscape-and-combination-approaches-to-improve-oncology-outcomes/353474.png","ImageObject",300,407,{"name":92,"@type":93},"MrHarris58","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What are the three key components of targeted radionuclide therapy (TRT)?","Question",{"text":112,"@type":113},"TRT typically includes a particle-emitting radionuclide, a linking complex (often with a chelator for radiometals), and a binding moiety that targets tumor-cell or tumor-microenvironment targets.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Why is TRT efficacy influenced by both radionuclide and delivery factors?",{"text":117,"@type":113},"TRT efficacy depends on target specificity, biodistribution, and radionuclide physical properties such as half-life, linear energy transfer (LET), and range, which must align with pharmacokinetics in tumor and normal tissues.",{"name":119,"@type":110,"acceptedAnswer":120},"How does the review justify combining TRT with other therapies?",{"text":121,"@type":113},"The document notes that most patients eventually relapse after TRT monotherapy. Combination strategies are discussed to enhance therapeutic index, improve cytotoxic effects, and modulate tumor target expression, with preclinical rationale and early clinical data supporting ongoing trials.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},353474,1790194592,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},687212988360,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Targeted Radionuclide Therapy: Current Landscape and Combination Approaches to Improve Oncology Outcomes  \nJulie Nonnekens1,2, Lauren A. Byers3, Aman Chauhan4, Daniel J. George5, Rodney J. Hicks6, and Wolfgang A. Weber7  \n|  |  | A |  | B | S |  | T | R |  | A |  | C | T |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n|  | Targeted radionuclide therapy (TRT) is an emerging modality in oncology that delivers internal radiation specifically to tumor sites. It typically consists of a particle-emitting radionuclide, a linking complex with a chelator for securely binding radionuclides to targeting molecules, and a binding moiety of targets expressed on tumor cells. Early clinical results have been promising, with several TRT agents approved for treating various cancers, including prostate cancer and gastroenteropancreatic neuroendocrine tumors, or their microenvironment. However, most patients eventually relapse following TRT monotherapy, leaving room to further improve patient outcomes. Combination strategies could be beneficial to improve therapeutic index, enhance cytotoxic effects, or modulate tumor\u003Cbr>􀀶 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | target expression; promising preclinical data have led to early-phase clinical trials. This review provides a concise overview of physical and chemical properties of commonly used β - and α-emitting radionuclides and a forward-looking rationale for combination regimens of TRT and other therapeutic modalities, such as hormone therapy, DNA damage repair inhibitors, immunotherapy, chemotherapy, external beam radiotherapy, and other combinations. We discuss the preclinical rationale, available clinical data, and ongoing key clinical trials with TRT combination therapy. Additionally, we highlight future perspectives including emerging radionuclides and prognostic and predictive biomarkers to optimize TRT combination therapy. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n\nIntroduction  \nTargeted radionuclide therapy (TRT) is an emerging strategy that delivers ionizing radiation specifically to tumor sites (1) . Radiopharmaceuticals are medicinal products for therapeutic use that usually comprise 3 key components: a particle-emitting radionuclide to treat tumor lesions with DNA-damaging radiation; a linking complex, typically with a chelator for radiometals; and a binding moiety of targets expressed on tumor cells or in the tumor microenvironment (TME; ref. 2) . Theranostics refers to the use of radiopharmaceuticals to visualize the intended treatment target through diagnostic positron emission tomography imaging using a positron-emitting radionuclide and to treat it by applying a therapeutic radionuclide bound to the same or a similar binding moiety (3–5) .  \n1Department of Radiology and Nuclear Medicine, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, the Netherlands. 2Department of Molecular Genetics, Erasmus MC Cancer Institute, Erasmus University Medical Center","cbCailM2zMz2fTAJ","https://ap.wps.com/l/cbCailM2zMz2fTAJ","pdf",1997514,11,"English","# Introduction\n# Targeted Radionuclide Therapy (TRT) Overview\n## Core Components and Mechanism\n## Theranostics and Imaging-to-Therapy Rationale","[{\"question\":\"What are the three key components of targeted radionuclide therapy (TRT)?\",\"answer\":\"TRT typically includes a particle-emitting radionuclide, a linking complex (often with a chelator for radiometals), and a binding moiety that targets tumor-cell or tumor-microenvironment targets.\"},{\"question\":\"Why is TRT efficacy influenced by both radionuclide and delivery factors?\",\"answer\":\"TRT efficacy depends on target specificity, biodistribution, and radionuclide physical properties such as half-life, linear energy transfer (LET), and range, which must align with pharmacokinetics in tumor and normal tissues.\"},{\"question\":\"How does the review justify combining TRT with other therapies?\",\"answer\":\"The document notes that most patients eventually relapse after TRT monotherapy. Combination strategies are discussed to enhance therapeutic index, improve cytotoxic effects, and modulate tumor target expression, with preclinical rationale and early clinical data supporting ongoing trials.\"}]","Targeted Radionuclide Therapy - Current Landscape and Combination Approaches to Improve Oncology Outcomes | PDF",1790105627,28,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b7824c006a71e7cbe6460e21b392ff97.webp",983,1315,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a2c2806ecbe950ca9bf19cd6e29218ec.webp",982,1314,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9055a4ed631cacc3cbc82009755935c4.webp",981,1312,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e465574a0d2d681f7725e858e181db7c.webp",980,1311]